APLS Q4 2020 Earnings — Apellis Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

APLSApellis Pharmaceuticals, Inc.

$3B

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$250M

Gross Profit

$250M99.9% margin

Operating Income

$130M52.0% margin

Net Income

$78M31.3% margin

EPS (Diluted)

$0.99

QoQ Revenue Growth

+38599.7%

Cash Flow

Operating Cash Flow

$142M

Free Cash Flow

$141M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$961M

Total Liabilities

$756M

Stockholders' Equity

$205M

Cash & Equivalents

$566M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$250M	$0	—
Gross Profit	$250M	-$215,858	+115787.2%
Operating Income	$130M	-$106M	+222.8%
Net Income	$78M	-$113M	+169.1%